Syneron Bio Raises $150M for Macrocyclic Peptide Drug Development
Beijing-based Syneron Bio raised $150M in Series B funding with AstraZeneca among investors to develop macrocyclic peptide drugs. The FDA also proposed a new expedited IND pathway.
#astrazeneca
2 stories
AstraZeneca Builds Phase II Obesity Pipeline Including Oral GLP-1 and Peptide Agents
AstraZeneca has oral GLP-1 agents (AZD5004), peptide therapies (AZD6234), and dual agonist combinations in its Phase II obesity pipeline.